Biotech
Welcome to the first "biotech mailbag" column. I get a lot of great reader email and feedback, which I try hard to answer directly. But often, there are questions asked or issues raised that could benefit a wider audience.
So consider this new regular column -- weekly, I hope, so keep the email flowing -- a chance to ask me questions about biotech or take me to task for something I wrote. I'll pick the best of the mail and address it here. Now, off to the mailbag.Elemer Piros, a research analyst at Rodman & Renshaw, is more bullish on Neurochem(NRMX) and its Alzheimer's drug Alzhemed than I was in my column this week. While he agrees that the ongoing Alzhemed phase III study is high-risk, he is more optimistic that results will be positive. Specifically, Piros says I neglected an issue with the study that girds his confidence. Piros writes that my column failed to "observe that these patients were on memory enhancers (80% on Aricept) on average for 20 months before they entered this 18-month study. You ignore the possibility that most of these patients were probably declining when they entered the study, and fail to reconcile this with the observation that 36% of the total (latest blinded analysis) has improved on average at the end of the 18 month experiment." (Piros has a market outperform rating on Neurochem, and his firm has done banking for the company in the past 12 months.)
TheStreet Premium Services
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn MoreOptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn MoreReal Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn MoreStocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,419.86 | 1,313.32 | 2,837.36 | 15.93 |
Oil *
103.11
|
|
DOWN
160.83 |
DOWN
19.10 |
DOWN
33.63 |
DOWN
0.32 |
10 Yr
1.59%
SPDR Gold
151.91
|
|
-1.28%
|
-1.43%
|
-1.17%
|
-1.97%
|
Data delayed 20 minutes |


Connect with TheStreet